论文部分内容阅读
目的研究布地奈德联合β_2受体激动剂雾化吸入治疗COPD急性发作的临床疗效。方法选在2011~2014年收治的46例疗COPD急性发作患者的临床资料.随机将患者分为观察组与对照组.各23例.对照组给予β2受体激动剂雾化吸入治疗.观察组采用布地奈德联合β_2受体激动剂雾化吸入治疗.比较两组患者的临床疗效、不良反应、血气分析情况.结果①观察组治疗总有效率为86.96%.对照组总有效率为65.22%.两组对比有统计学意义(P<0.05).②观察组的二氧化碳分压、氧气分压与对照组相比有统计学意义(P<0.05)。③观察组不良反应病例为9例.发生率为39.13%。对照组不良反应病例为10例.发生率为43.38%,对比无统计学意义(P>0.05).结论布地奈德联合雾化吸入β_2受体激动剂在COPD急性发作治疗中应用效果非常显著.有利于促进患者疾病症状的改善,不会增加患者不良反应.临床治疗安全性高.值得临床推广应用。
Objective To study the clinical efficacy of budesonide combined with β 2 receptor agonist nebulization in the treatment of acute exacerbation of COPD. Methods Forty-six patients with acute exacerbation of COPD were enrolled in this study from 2011 to 2014. The patients were randomly divided into observation group and control group, with 23 cases in each group.The control group was treated with inhalation of β2-receptor agonist.The observation group Adopting budesonide combined with β_2 receptor agonist inhalation therapy.Clinical efficacy, adverse reactions, blood gas analysis were compared between the two groups.Results ① The total effective rate of the observation group was 86.96% .The total effective rate of the control group was 65.22% (P <0.05) .②The partial pressure of carbon dioxide and partial pressure of oxygen in the observation group were statistically significant compared with the control group (P <0.05). The observation group of adverse reactions in 9 cases, the incidence was 39.13%. The incidence of adverse reactions in the control group was 10. The incidence rate was 43.38%, with no significant difference between the two groups (P> 0.05) .Conclusion Budesonide combined with inhaled β_2 receptor agonist has a significant effect in the treatment of acute exacerbation of COPD. Will help to improve the symptoms of patients with disease, will not increase the adverse reactions in patients with high clinical safety. Worth clinical application.